Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC

BACKGROUND: Numerous clinical trials show crizotinib has promising efficacy for anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients which trigger the substitution of traditional chemotherapy to be the current standard first-line treatment for these patients. Convers...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Zhu, Qian, Hu, Hao, Jiang, Feng, Guo, Chang Ying, Yang, Xiong Wen, Liu, Xi, Kuang, Yu Kang
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5650427/
https://ncbi.nlm.nih.gov/pubmed/29088872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18536
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares